IMUX:NASDAQImmunic, Inc. Analysis

Immunic (IMUX) trades at $1.19, comfortably above its 20‑day ($1.18) and 50‑day ($1.03) SMAs and the 200‑day SMA ($0.85), signaling a short‑term bullish bias. The RSI sits at 53, indicating neutral‑to‑slightly‑bullish momentum, while the MACD histogram is marginally negative, hinting at a near‑term pull‑back. Volatility is extreme at over 107% (30‑day) and beta exceeds 1.4, underscoring heightened price swings. The stock sits near a support level of $1.03 with resistance around $1.40, and the model projects a 341% upside to a mean target of $5.25, suggesting substantial valuation room.
Fundamentally, IMUX reports zero revenue, sizable operating losses (EBITDA –$103M) and negative cash flow, with a modest cash balance of $15.5M. However, the company recently secured a key European patent extending protection for its lead MS candidate to 2038 and attracted new buy coverage from Guggenheim with a $7 price target. Regaining Nasdaq minimum‑bid compliance further removes a near‑term delisting risk, providing a catalyst that could help the stock move toward its lofty upside potential.